Trident Lifeline Ltd Stock Price Today (NSE: TLL)
Fundamental Score
Trident Lifeline Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Trident Lifeline Ltd share price today is ₹404.75, up +9.81% on NSE/BSE as of 22 September 2026. Trident Lifeline Ltd (TLL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹482.99 (Cr). The 52-week high for TLL share price is ₹371.00 and the 52-week low is ₹229.95. At a P/E ratio of 24.09x, TLL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 21.95% and a debt-to-equity ratio of 0.73.
Trident Lifeline Ltd Share Price Chart — NSE/BSE Historical Performance
Trident Lifeline Ltd share price chart: 14.22% return over the past month. 52-week high ₹371.00, 52-week low ₹229.95.
Trident Lifeline Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹322.55 | ₹371.00 | ₹316.20 | ₹368.60 | 1.19L (Cr) | |
| ₹310.00 | ₹318.00 | ₹310.00 | ₹315.05 | 9.00K (Cr) | |
| ₹298.00 | ₹310.00 | ₹298.00 | ₹305.55 | 76.80K (Cr) | |
| ₹295.00 | ₹312.75 | ₹294.40 | ₹303.55 | 63.00K (Cr) | |
| ₹300.05 | ₹300.05 | ₹280.00 | ₹284.05 | 2.93L (Cr) | |
| ₹297.00 | ₹303.90 | ₹291.00 | ₹302.50 | 66.60K (Cr) | |
| ₹294.00 | ₹299.90 | ₹291.05 | ₹297.35 | 27.60K (Cr) | |
| ₹290.00 | ₹297.00 | ₹285.00 | ₹294.00 | 21.00K (Cr) | |
| ₹293.00 | ₹294.85 | ₹285.00 | ₹287.50 | 22.20K (Cr) | |
| ₹300.00 | ₹308.00 | ₹290.00 | ₹291.35 | 27.60K (Cr) |
Trident Lifeline Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹272.95 | ₹371.00 | ₹270.00 | ₹368.60 | +35.04% | |
| ₹266.05 | ₹268.00 | ₹250.00 | ₹263.80 | -0.85% | |
| ₹266.00 | ₹275.00 | ₹251.65 | ₹262.90 | -1.17% | |
| ₹255.75 | ₹280.00 | ₹240.00 | ₹270.90 | +5.92% | |
| ₹249.00 | ₹277.50 | ₹242.00 | ₹249.50 | +0.20% | |
| ₹306.00 | ₹306.00 | ₹240.00 | ₹250.05 | -18.28% | |
| ₹268.00 | ₹272.45 | ₹229.95 | ₹268.35 | +0.13% | |
| ₹297.25 | ₹303.00 | ₹245.10 | ₹269.00 | -9.50% | |
| ₹312.00 | ₹328.00 | ₹288.00 | ₹297.25 | -4.73% | |
| ₹307.55 | ₹324.00 | ₹265.00 | ₹310.70 | +1.02% | |
| ₹297.00 | ₹320.00 | ₹288.00 | ₹315.75 | +6.31% | |
| ₹284.35 | ₹322.85 | ₹284.35 | ₹300.00 | +5.50% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Trident Lifeline Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Trident Lifeline Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TLL across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (21.95%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.91%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (19.22%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 24.09 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (63.90%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Interest Coverage (7.60x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.69)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (62.59%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-92.32 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 7.51%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Trident Lifeline Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Trident Lifeline Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Trident Lifeline LtdTrident Lifelin...Selected✓ TLL • 543616 | 46.3/100 | ₹404.75₹405 | ₹482.99₹482.99 | 24.09Average 24.1 Average | 21.95%Excellent 21.95% Excellent | 24.91%Excellent 24.91% Excellent | 0.73Good 0.7 Good | — — | — — | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Trident Lifeline Ltd PE Ratio History
Historical price-to-earnings ratio for TLL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹10.22 | ₹310.70 | 30.4x |
| FY 2024 | ₹5.52 | ₹280.00 | 50.7x |
| FY 2023 | ₹6.22 | ₹188.00 | 30.2x |
| FY 2022 | ₹3.43 | ₹124.00 | 36.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Trident Lifeline Ltd Quarterly Performance
Latest quarterly metrics for TLL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
13.70%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
63.90%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Trident Lifeline Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for TLL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Trident Lifeline Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Trident Lifeline Ltd (TLL) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Trident Lifeline Ltd
About TLL (Trident Lifeline Ltd)
Trident Lifeline Ltd is a global pharmaceutical organization dedicated to enhancing health outcomes through the development, production, and distribution of a diverse portfolio of ...therapeutic solutions. From our state-of-the-art manufacturing facilities, we craft a wide array of formulations encompassing both conventional and innovative approaches to healthcare. Our product range extends from essential medicines addressing prevalent health challenges to specialized nutraceuticals designed to promote wellness and preventative care. TLL is driven by a commitment to uncompromising quality and rigorous adherence to international regulatory standards, ensuring that every product delivers optimal efficacy and safety to the patients who rely on us. At Trident Lifeline, we are deeply invested in expanding access to quality healthcare across the globe. We operate with a robust network of partners and distributors, allowing us to reach diverse populations with our comprehensive range of medicinal products. Our focus lies in providing tailored solutions that meet the specific needs of different markets, while remaining committed to ethical business practices and sustainable development. By continuously investing in research, development, and strategic partnerships, TLL is poised to remain at the forefront of pharmaceutical innovation, adapting to the evolving healthcare landscape and addressing unmet medical needs. Our commitment to innovation is reflected in the breadth of our offerings, which include not just traditional tablets and capsules, but also advanced delivery systems designed to improve patient adherence and therapeutic outcomes. With a comprehensive understanding of patient needs and market trends, Trident Lifeline is committed to developing and manufacturing formulations that combine efficacy, safety, and convenience. We strive to be a trusted partner in healthcare, empowering patients and providers with the tools they need to improve lives and build healthier communities.
Company Details
Key Leadership
TLL Share Price: Frequently Asked Questions
What is the current share price of Trident Lifeline Ltd?
Trident Lifeline Ltd (TLL) trades at ₹404.75 on NSE and BSE. Market cap ₹482.99 (Cr). Educational data only.
What is the P/E ratio of Trident Lifeline Ltd?
Trident Lifeline Ltd has a P/E of 24.09x vs industry average 34.89x.
What is the Bull Run score for Trident Lifeline Ltd?
Trident Lifeline Ltd has a Bull Run score of 46.3/100 based on 25+ financial parameters.
Does Trident Lifeline Ltd pay dividends?
Trident Lifeline Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Trident Lifeline Ltd?
Trident Lifeline Ltd has ROE of 21.95%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Trident Lifeline Ltd?
Trident Lifeline Ltd has debt-to-equity of 0.73.
Is Trident Lifeline Ltd a good investment?
Bull Run gives Trident Lifeline Ltd a score of 46.3/100. This is not investment advice — consult a SEBI-registered advisor.